12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Galeterone: Phase II started

Tokai began the 2-part, open label, international Phase II ARMOR2 trial to evaluate oral galeterone once daily for about 3 months in up to 196 patients who are treatment-naïve or who have progressed following Zytiga abiraterone acetate therapy....

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >